Tobacco, nicotine, and cannabis use and exposure in an 1 Australian Indigenous population during pregnancy: A protocol 2 to measure parental and foetal exposure and outcomes. 3 4 5 Angela Ratsch^{1,2}, Elizabeth A. Burmeister^{1,2}, Aunty Veronica Bird³, Aunty Joyce 6 7 Bonner³, Uncle Glen Miller^{3,4}, Aunty Mari Speedy³, Graham Douglas⁵, Stevan Ober⁵, Ann Woolcock⁵, Sharly Blair (nee Murdoch)⁵, Min-Tz Weng⁶, Jared A. Miles⁶, Kathryn 8 9 I. Steadman⁶ 10 11 12 ¹ Wide Bay Hospital and Health Service, Hervey Bay, Australia ² Rural Clinical School, The University of Queensland, Brisbane, Australia 13 ³ Butchulla Aboriginal Corporation, Fraser Coast, Australia 14 15 ⁴ Butchulla Mens Business Association, Fraser Coast, Australia ⁵ Galangoor Duwalami Primary Healthcare Service, Fraser Coast, Australia 16 17 ⁶ School of Pharmacy, The University of Queensland, Brisbane, Australia 18 19 *Corresponding author 20 E-mail: angela.ratsch@health.qld.gov.au 21 22

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Tobacco, nicotine, and cannabis use and exposure in an Australian Indigenous population during pregnancy: A protocol to measure parental and foetal exposure and outcomes. Abstract Background: The Australian National Perinatal Data Collection collates all live and stillbirths from States and Territories in Australia. In that database, maternal cigarette smoking is noted twice (smoking < 20 weeks gestation; smoking > 20 weeks gestation). Cannabis use and other forms of nicotine use, for example vaping and nicotine replacement therapy, are nor reported. The 2021 report shows the rate of smoking for Australian Indigenous mothers was 42% compared with 11% for Australian non-Indigenous mothers. Evidence shows that Indigenous babies exposed to maternal smoking have a higher rate of adverse outcomes compared to non-Indigenous babies exposed to maternal smoking. **Objectives:** The reasons for the differences in health outcome between Indigenous and non-Indigenous pregnancies exposed to tobacco and nicotine is unknown but will be explored in this project through a number of activities. Firstly, the patterns of parental and household tobacco, nicotine and cannabis use and exposure will be mapped during pregnancy. Secondly, a range of biological samples will be collected to enable the first determination of Australian Indigenous people's nicotine and cannabis metabolism during pregnancy; this assessment will be informed by pharmacogenomic analysis. Thirdly, the pharmacokinetic and pharmacogenomic

findings will be considered against maternal, placental, foetal and neonatal outcomes.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Lastly, an assessment of population health literacy and risk perception related to tobacco, nicotine and cannabis products peri-pregnancy will be undertaken. **Methods:** This is a community-driven, co-designed, prospective, mixed-method observational study with regional Queensland parents expecting an Australian Indigenous baby and their close house-hold contacts during the peri-gestational period. The research utilises a multi-pronged and multi-disciplinary approach to explore interlinked objectives. Results: A sample of 80 mothers expecting an Australian Indigenous baby will be recruited. This sample size will allow estimation of at least 90% sensitivity and specificity for the screening tool which maps the patterns of tobacco and nicotine use and exposure versus urinary cotinine with 95% CI within ±7% of the point estimate. The sample size required for other aspects of the research is less (pharmacokinetic and genomic n=50, and the placental aspects n=40), however from all 80 mothers, all samples will be collected. **Conclusions:** Results will be reported using the STROBE guidelines for observational studies. **Keywords:** Tobacco; nicotine; cannabis; exposure; pregnancy, pregnancy outcomes; Aboriginal and Torres Strait Islander; Australian Indigenous.

Forward

We acknowledge the Traditional Custodians, the Butchulla people, of the lands and

waters upon which this research is conducted. We acknowledge their continuing

connections to country and pay our respects to Elders past, present and emerging.

Notation: In this document, the terms Aboriginal and Torres Strait Islander and

Indigenous are used interchangeably for Australia's First Nations People. No

disrespect is intended, and we acknowledge the rich cultural diversity of the groups

of peoples that are the Traditional Custodians of the land with which they identify

and with whom they share a connection and ancestry.

Introduction

In 1957, Simpson [1] reported a dose-response association between maternal smoking and premature birth. This observation resulted in a world-wide research agenda focusing on the impact of maternal smoking in pregnancy, the findings of which indicate that maternal tobacco smoking, and exposure to the products of tobacco combustion (i.e., secondhand smoke exposure) are the leading modifiable risk behaviours associated with adverse maternal and neonatal outcomes. Maternal exposure increases the risk for miscarriage, ectopic pregnancy, antepartum bleeding, placental abruption, placenta previa, postpartum haemorrhage and alters maternal thyroid function [2, 3]. Counterintuitively, smoking in pregnancy is associated with decreased hypertensive disorders of pregnancy [4, 5]. For the foetus, maternal

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

exposure increases the risk of stillbirth, premature birth and lower birthweight [6] as well as increases the risk for a number of congenital abnormalities [7, 8]. Longerterm, offspring exposed in-utero to maternal smoking have decreased cognitive achievement [9] and an increased risk for the development of attentiondeficit/hyperactivity disorder (ADHD) [10]. In Australia, these adverse pregnancy and foetal findings have ensured a prenatal focus on maternal smoking behaviour with the mother's cigarette smoking status obtained during antenatal assessment and recorded in the National Perinatal Data Collection [11] twice across the nine months of pregnancy (once < 20 weeks gestation, and once >20 weeks gestation). In that database, the 2021 rate of smoking by Australian non-Indigenous expectant mothers was reported as 11% compared with 42% by Australian Indigenous expectant mothers [12]. However, the maternal use of other tobacco and nicotine products including e-cigarettes, hookahs, chop-chop tobacco, nicotine tooth cleaning powder, chewing tobacco, and nicotine spray, mist, lozenges, gum and patches, and cannabis is not collected. In addition, this focus on maternal cigarette smoking fails to recognise second- and third-hand maternal nicotine vape and tobacco and cannabis smoke exposure, i.e., the impact from paternal and household tobacco, nicotine and cannabis exposure on maternal and foetal outcomes is overlooked. This assessment gap results in maternal and foetal tobacco, nicotine and cannabis exposure misclassification and ramifications in the planning of care, and in the estimation of adverse maternal, placental, foetal and neonatal outcomes from

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

tobacco, nicotine and cannabis exposure. Nevertheless, the literature indicates that Indigenous babies exposed to maternal smoking have a higher rate of adverse outcomes compared to non-Indigenous babies exposed to maternal smoking, for example, after adjusting for maternal age and other factors, smoking in pregnancy is attributable to 22% of pre-term Indigenous births compared with 5% for non-Indigenous births [13]. Gestational age impacts birthweight, and for Indigenous mothers who smoked in the first 20 weeks of pregnancy, the risk of a lower birthweight baby was 1.8 (or about 80% higher risk) than among Indigenous mothers who did not smoke in the first 20 weeks. For non-Indigenous mothers who smoked in pregnancy, this risk was 1.3 (or 30% higher risk) [14]. The other significant foetal outcome attributable to maternal smoking is stillbirth. In Australia, stillbirth is defined as foetal death prior to birth of the baby at 20 weeks gestation or more, and/or weighing 400 grams or more [15]. In 2020, the overall Australian stillbirth rate was 7.7/1000 births, with the rate for Indigenous mothers being 11.9/1000 compared with 7.4/1000 for non-Indigenous mothers. Smoking in pregnancy is a risk factor for stillbirth; for women who smoked in pregnancy, the stillbirth rate was 12.8 stillbirths/1000 births compared to 6.9 stillbirths/1000 births for mothers who did not smoke [15]. Sub-category analysis of smoking and stillbirth for Indigenous mothers compared to non-Indigenous mothers is not published. The reasons for the differences in pregnancy outcome between Indigenous and non-Indigenous pregnancies exposed to tobacco and nicotine are unknown but will be explored in this project through a number of activities.

Background

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

Nicotine: pregnancy health and the developing human

Currently, tobacco assessment in pregnancy is focused on 'smoking'. This emphasis overlooks the absorption of the pharmacologically active, dose-dependent, potentially lethal component of tobacco-which is nicotine-from other sources [16]. This study is premised on some of the actions of nicotine. In brief, nicotine binds with and activates nicotinic acetylcholine receptors (nAChR) in central and peripheral neuronal and non-neuronal tissue, at neuromuscular junctions, and in the adrenal medulla [17]. Receptor type and individual variability, including genetics and pregnancy, result in receptor up-regulation or desensitization [16, 18] and the release of neurotransmitters including acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin and adreno-corticotropic-hormone, thus impacting the vasculature and producing vasoconstriction, increasing heart rate and blood pressure [19]. In pregnancy, nicotine acts both directly on nAChRs in the developing placenta, reducing the number of nAChR receptors [20], and alters placental morphology and vascularity [21]. Nicotine also readily crosses the placenta and stimulates nAChRs in the developing foetus impacting foetal systems, albeit in an immature physiology [22]. During early foetal development (4-6 weeks of gestation), nAChRs emerge and begin to form connections throughout the body including the brain [23], with construction of axons and synaptic connections in the brain continuing after birth into childhood, adolescence and young adulthood [24]. In the foetal brain, nicotine exposure results in accelerated cell development relative to tissue and organ age, that is, there are fewer cells correctly developed for their stage and age [25]. Following nicotine exposure, changes in nAChRs and neural plasticity result in both a deficit in the number of neurons in the foetal brain and synaptic level damage to the respiratory center, with equivalent damage to the adrenal glands [26]. Foetal nicotine exposure ultimately results in a dampened response to hypoxic episodes [27]. These physiological changes are important in understanding links between maternal nicotine exposure and foetal outcomes, for example, stillbirth and Sudden Infant Death Syndrome (SIDS).

Nicotine metabolism and excretion

Nicotine has a half-life of about two hours and is metabolised via the CYP2A6 pathway primarily in the liver, with the brain, kidneys and lungs providing minor sites [28]. This short half-life produces large nicotine serum plasma fluctuations and poses challenges for intra- and inter-person comparisons of exposure, consumption and effect. However, cotinine (the main tobacco and nicotine metabolite) has a half-life of approximately 17 hours and serum concentrations 10-fold higher than nicotine, providing a more stable biomarker of tobacco and nicotine exposure [29]. Cotinine begins to metabolise after approximately 16 hours into trans-3'-hydroxycotinine (3-OH-cotinine), nornicotine, nicotine glucuronide and nicotine-N-oxide [18]. A more

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

accurate assessment of tobacco and nicotine exposure is achieved by measuring serum tobacco and nicotine and metabolite concentrations (total nicotine equivalents - TNE), as opposed to measuring only nicotine concentration [30]. During pregnancy, nicotine metabolism is impacted both by individual variability [16] and the changes created by pregnancy. In the expectant mother, there is a significant induction of CYP2A6 activity which increases plasma clearances of nicotine by 60% and cotinine by 140%, in addition, there is an almost 50% reduction in cotinine half-life (down from 17 hours to 9 hours [31]). This is important in the consideration of tobacco and nicotine use in pregnancy as decreases in nicotine and cotinine measurements in late pregnancy compared with pre-pregnancy or early pregnancy may not necessarily indicate a decrease in tobacco and nicotine exposure, but rather the more rapid metabolism of nicotine [32]. In the foetus and neonate, the immature and undeveloped CYP2A6 pathway decreases their ability to metabolise nicotine and results in a much longer plasma nicotine half-life than adults (11.2 hours compared to 2 hours) whereas cotinine elimination is similar to that of adults (16.3) hour half-life compared with 17 hours) [33]. CYP2A6, the major nicotine-oxidising enzyme, is measurable using the nicotine metabolite ratio (NMR; 3'hydroxycotinine:cotinine) and is a biomarker of nicotine clearance [16]. However, NMR is highly heritable (~80%) varying with ethnicity, in part due to CYP2A6 variants. Variation in CYP2A6 genes has not been characterised

in Australian Indigenous populations and may contribute to increased/decreased pregnancy risk from tobacco and nicotine exposure.

Tobacco, nicotine and the metabolites are rapidly excreted by the kidneys with the rate dependent upon urinary pH, where increased urine alkalinity decreases excretion [34]. Urinary excretion is further impacted in pregnancy due to elevated creatinine potentially leading to fluctuations in nicotine and its metabolites [35]. Thus, serum provides a measure of exposure and the recency of that exposure, while urine analysis provides a measure of tobacco and nicotine metabolism and excretion.

Materials and Methods

Aim and Objectives

The aim of this study is to develop a foundation from which approaches to tobacco and nicotine assessment, health literacy, tobacco and nicotine cessation, and maternal and neonatal health care delivery for families expecting an Australian Indigenous baby is informed by contemporary evidence. Community input on the design suggested that cannabis use (with and without tobacco) is also prevalent and continues throughout pregnancy, thus cannabis use and exposure have been included.

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

The objectives are to: 1. Accurately describe parental and close household contact(s) peri-gestational patterns of use and exposure of tobacco, nicotine and cannabis products through the creation and use of a validated assessment tool. 2. Determine the pharmacokinetic and pharmacogenomic impacts and outcomes of tobacco, nicotine and cannabis exposure. This study will be the first to establish the metabolism of tobacco, nicotine and cannabis during pregnancy by using NMR as a biomarker of individual differences in nicotine and cannabis metabolism in a parental Australian Indigenous population. 3. Describe maternal, paternal, placental, foetal and neonatal outcomes according to the use and exposure to tobacco, nicotine and cannabis products and biochemical and genomic analysis. 4. Describe the influences and barriers to cessation for pregnant Australian Indigenous families or close household contacts to reduce or cease tobacco, nicotine and/or cannabis use in pregnancy. **Research Governance** This project is centred around the local Australian Indigenous population in the Fraser Coast area (Queensland, Australia). The research will be conducted primarily from Galangoor Duwalami Primary Healthcare Service (the local Aboriginal and

Torres Strait Islander Primary Health Service in Hervey Bay and Maryborough) and

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

at the Hervey Bay and Maryborough Hospitals within the Wide Bay Hospital and Health Service (WBHHS). Galangoor Duwalami Primary Healthcare Service were consulted in regard to which Community members would best represent the Traditional Owners of the land where this research is to be conducted. A combined leadership group was formed which included the Butchulla Aboriginal Corporation and Butchulla Men's Business Association and this group advised, directed and oversaw the conversations around this research from its inception and arranged for discussions with the appropriate Community members. Under the Butchulla Aboriginal Corporation's Rule Book, the principal Objective of the corporation is to: 'Relieve poverty and disadvantage of the Butchulla People through the advancement of education, health, social or public welfare, and culture'. Accordingly, the Elders have approved this proposal and provided a Butchulla name for the project – *Ngabang* (mother), *Walbai* (baby), *Babun* (father). The project logo (Figure 1) reflects the aspirations of the Butchulla people for this project, which are to strive for a *healthy pregnancy*, which results in a *healthy* family, which maintains a healthy culture. Figure 1 Project logo The logo also recognises the governance of the project by the Butchulla people, Galangoor Duwalami Primary Healthcare Service, the various Australian research

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

guidelines, and the collaborative nature of the project with other health providers and research-intensive organisations and academic partners. The project documentation, and staff and participant shirts and onesies carry this logo (Figure 2) and 3) Figure 2 Participant shirt Figure 3 Participant onesie Research context Galangoor Duwalami Primary Healthcare Service generally maintain the sole care of the pregnant women until approximately 20 weeks gestation (unless they have a high-risk pregnancy). The mother then moves to a shared care model with the Hervey Bay and Maryborough Hospitals. In this project, data is collected across the entire pregnancy. The preferred site of data collection from Galangoor Duwalami Primary Healthcare Service patients will be at Galangoor Duwalami Primary Healthcare Service for as long as possible during the pregnancy, however some data collection will need to occur at antenatal visits at the Hervey Bay or Maryborough Hospitals. At birth (mostly likely at the Hervey Bay Hospital), biological samples will be collected, and birthing data will be collected on the participant's discharge from hospital. Inclusion and exclusion criteria and consent Potential participants who meet the following criteria will be invited to enrol in the study: pregnant mothers, aged 15 years or older at the time of enrollment, able to

understand English, able to provide informed consent, and who self-identify as being

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

pregnant with an Australian Indigenous baby. In accordance with the value of Respect outlined in the National Statement of Ethical Conduct in Human Research [36], all potential maternal participants meeting the inclusion criteria will be carefully considered by the clinic midwife or healthcare medical officer to ensure the healthcare staff believe that potential enrolment is in the best interest of the participant at this point in their pregnancy. A list of suitable potential maternal participants will then be provided to the researchers; only those participants will be provided with research information. The project will strive to enrol the family unit i.e., the mother, and the foetus, and the biological father, or non-biological parent partner (the parents), or one close household contact. For example, if an expectant mother lives with her sister or aunty or grandmother but there is no biological father in the family at that time, or there is a partner (of either gender) and that close family contact attends the antenatal visits with the maternal participant, that person will be invited to participate with the expectant mother. Family members do not have to participate; however, 'family' is central to Australian Indigenous people, and enrolling participants who constitute the cultural norm of family will be especially important in the translation of findings to the participant and the community. Consent: Participants can choose to enrol in any or all aspects of the data and sample collection, and they can withdraw from any or all aspects of the research at any time.

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

The consent process enables participants to choose to have their individual results provided back to them at the completion of the project; for any or all samples to returned to the participant on completion of this project; or for the de-identified samples and de-identified data to be retained for ethically approved un-identified projects in the future. All enrolled participants will receive a participant shirt (Figure 2), and liveborn newborns will receive a project onesie (Figure 3). A subset of information-rich tobacco, nicotine and/or cannabis use/exposed participants will be enrolled into the separate male and female qualitative aspects of the study until saturation is reached (~ 30 participants). Data will be collected in response to a range of trigger questions and survey questions. Participants enrolled in the qualitative data collection will receive a \$50 grocery voucher in acknowledgement of their time to the project. Tobacco, nicotine and cannabis use and exposure data and biological sample collection The quantitative data and sample collection for Objectives 1-3 is designed to measure maternal tobacco, nicotine and cannabis use, and maternal and foetal exposure, metabolism and excretion at varying times throughout the pregnancy and assess the findings against the maternal and foetal outcomes. At each antenatal appointment and at birth, tobacco, nicotine and cannabis use and exposure information will collected on a NicOTIne, tobacco, and Cannabis use and Exposure (**NOTICE**) Assessment Tool (Figure 4 and see Box 1 NOTICE Notes).

Figure 4 NOTICE: NicOTIne, tobacco, and Cannabis use and Exposure (NOTICE)

Assessment Tool

335

336

337

338

339

Box 1. NicOTIne tobacco, and Cannabis use and Exposure (NOTICE)

Assessment Tool - Notes.

The NicOTIne tobacco, and Cannabis use and Exposure (NOTICE) assessment tool (Figure 4) has been developed by Angela Ratsch for this study to enable a comprehensive assessment of the use of smoked and smokeless tobacco and cannabis products as well as nicotine containing products. The tool also allows for the detailing of second-hand exposure, and is used in this protocol to inform the use and exposure of all products throughout the pregnancy. The recorded information facilitates a scoring method to determine the level of self-reported use and exposure to tobacco, nicotine and cannabis products (scored for the day of assessment, previous 24 hours, and the previous week).

A self-use weekly score will be calculated for each assessment completed. Scoring for self-use will be categorized for each product as: 0 - no use; 1 - low use (1 to 70 combusted or inhaled products); 2 - medium use (71-140 combusted or inhaled products); 3 - high use (141 + combusted or inhaled products). A self-use score will be calculated for each weekly product combusted or inhaled with the sum of these scores producing a total weekly self-use score with a range of 0-30. An exposure score will be calculated for each weekly product exposed to by multiplying the quantity exposed to score by the exposure. Exposure is categorized as 0 - no exposure; 1- some

limited exposure; 2 -moderate exposure or 3 - unrestricted exposure. A total weekly exposure score is then calculated by summing all the exposure scores with a range of 0-99 for each assessment completed.

The assessment takes about 3 minutes to complete and will be conducted at each antenatal visit and immediately prior to birth.

Exhaled breathe carbon monoxide (CO) assessment

CO as a point of care (POC) assessment provides indicative information about combusted tobacco/cannabis use up to 24 hours previously. Exhaled CO monitors (Smokerlyser®) provide a CO ppm reading ranging between 0 and 30 and a percentage of oxygen replaced with CO on haemoglobin (%COHb) with higher readings indicating higher levels of combusted tobacco/cannabis use. The same device can measure foetal exposure as foetal carboxyhaemoglobin (%FCOHb). Readings for the level of CO ppm are categorized as:

- green—for no and general environmental combusted tobacco/cannabis exposure, indicated by CO <3 ppm for pregnant women, and CO <6 ppm for non-pregnant adults;
- orange—moderate combusted tobacco/cannabis exposure, indicated by CO 4 6 ppm for pregnant women, and CO 7-10 ppm in non-pregnant adults and;
- red—heavy combusted tobacco/cannabis exposure, indicated by CO >6 ppm
 for pregnant women, and CO >10 ppm in non-pregnant adults.

The assessment takes about 1 minute to complete and will be conducted at each antenatal visit and immediately prior to birth.

17

Saliva cotinine assessment

The use of non-combusted tobacco products and nicotine substances, for example, chewed tobacco, e-cigarettes, nicotine patches and gum, does not create CO. Instead, cotinine saliva assessment (Oz Drug Tests®), as a POC measurement, can detect cotinine (the major metabolite of nicotine metabolism). The test has a cotinine cut-off value of 10 ng/mL and the expected window of detection for cotinine in saliva at 10 ng/mL is expected to be up to 2-3 days after the last nicotine use. The assessment takes about 3 minutes to complete and will be conducted at each antenatal visit and immediately prior to birth.

Procedure: The CO assessment will be conducted first, and if the CO level is within the yellow or red zone (high levels), a saliva test will not be conducted as these CO levels are indicative of combusted tobacco use and negates the requirement for saliva testing.

Sample collection process

342 Mother

340

341

343

344

345

346

347

348

At the first antenatal appointment, maternal urine, CO and saliva samples will be

collected on a NOTICE Tool.

If the CO is within the orange or red zones, a cotinine saliva test will not be

conducted. Also, during this first appointment, or when maternal bloods are being

collected as part of standard care, maternal vein blood will be collected for this

project.

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

• At each follow-up antenatal visit, maternal urine, CO and saliva (if indicated) will be collected and a NOTICE assessment completed. Biological father • At the first antenatal appointment, if the biological father is Indigenous, paternal vein blood, urine and semen will be collected and CO, saliva (if indicated), and a NOTICE assessment completed. • At each follow-up visit, the biologically paternal CO and saliva (if indicated) samples will be measured and a NOTICE assessment completed. Non-biological parent, partner or close household member At the first antenatal visit, the non-biological parent partner or close household contact will have a CO and saliva (if indicated) measured and a NOTICE assessment completed and these same tests will be conducted at each visit. *Unaccompanied mother* If the biological father, partner or household member is not present, the expectant mother will report her exposure to the partner's and/or household member's combusted tobacco or heated nicotine (e-cigarette) as second-hand exposure on the NOTICE assessment tool. At birth On presentation for birth, mothers will have a venous blood sample, urine, CO and saliva samples (if indicated) collected and a NOTICE assessment will be completed. At spontaneous or artificial rupture of membranes or caesarean birth, amniotic fluid will be collected.

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

Following birth and the separation of the placenta from the mother and neonate, arterial and venous cord bloods will be collected from the placenta. The placenta will be weighed in grams, and measured in centimetres at two points, the widest and narrowest to estimate the area of the placenta. Placental photographs of the maternal and foetal side and the cord will be obtained. Placental samples for macro, micro-morphological and genomic examination will be obtained, rinsed in a solution of phosphate buffered saline and distilled water and then placed in a solution of RNA later. The placenta sent for standard histology. Postnatal Following birth, neonates will have a Day 0-1 urine and meconium collected. If the neonate remains in hospital after Day 1, a further urine sample will be collected. The urine will be collected with the use of a standard adhesive urine collection devise, and meconium will be collected from the nappy. Colostrum/breast milk will be collected when available. As active participants in the knowledge generation from this research, mothers will be encouraged to obtain their own colostrum/breast milk sample by hand/pump expression. **Clinical information** Data contained in the Galangoor Duwalami Primary Healthcare Service and Hospital record including demographic, maternal, and neonatal data will be included in the research database. Pregnancy, labour and birthing information will be collected from the Queensland Health Perinatal Record following birth.

Biological sample analysis.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

After labelling, participant samples will be stored in the appropriate solution and/or temperature control manner. Placental samples in RNA later will be transferred to the University of the Sunshine Coast for storage at -80°C. Other samples (excluding the whole placenta in formalin) will be transferred to the local Sullivan and Nicolaides Pathology at standard intervals. Sullivan and Nicolaides will then transfer directly to The University of Queensland for storage at -80°C. The placenta in formalin will be transferred to Queensland Pathology. The scientists undertaking the biological examinations and analysis will be blinded to the self-reported tobacco, nicotine and cannabis status of the participant. Pregnancy elevates creatinine levels, potentially leading to fluctuations in the levels of nicotine and its metabolites and influencing cannabinoid levels [35]. To ensure the standardisation of these levels in urine samples during pregnancy, a creatinine analysis will be conducted. The biological samples will be initially analysed for tobacco, nicotine and their metabolites and cannabinoid concentration in ng/mg creatinine or nmol/mg creatinine for urine samples and ng/mL for other biological samples using standard procedures. Following this, the samples will undergo tobacco, nicotine and cannabinoid genomic assessment in relation to tobacco, nicotine and cannabis pharmacokinetics, and other examinations including thyroid antibodies, transthyretin and sENG levels and a genomic-wide analysis of tobacco nicotine and cannabis induced alterations will be conducted. In addition, the colostrum/breast milk microbiome will be considered for the impact of tobacco, nicotine and cannabis exposure.

Qualitative data collection

Information-rich participants will be invited to take part in a face-to-face interview and survey. The interview and survey will be in the form of a yarn [37-39] which will be conducted at a place of the participants choosing and audio recorded for review. Participants are welcome to have support people with them should they wish. Data will be responses to a range of trigger questions and survey questions to consider the barriers and influences to tobacco, nicotine and cannabis use and cessation, and to understand the population's health literacy and risk perception related to tobacco, nicotine and cannabis products peri-pregnancy. Participant's own language and slang will be used when possible. Data will be collected in a coded, but re-identifiable manner to enable researcher and participant follow-up. The code that will be used will be the same as for the participant's biological and clinical data collection. The codebook will be kept in a separate location to the recording. During the interviews, the participant will only be identified by the unique code.

Outcome assessment

Enrollment maternal blood and urine samples provide a baseline and are correlated to exhaled carbon monoxide (CO), cotinine saliva assessment, and the self-reported tobacco, nicotine and cannabis assessment tool (see Figure 4 and Notes: Table 1). At each antenatal visit, maternal urine is collected and correlated to the CO and saliva assessment and the self-reported tobacco, nicotine and cannabis assessment tool. At birth, a second maternal blood is taken to correlate to the excretion of nicotine and cannabis by the mother and neonate as measured in maternal and neonatal urine,

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

breast milk and meconium. The transfer of nicotine and cannabis to the foetus through the placenta and return to the mother is measured by amniotic fluid, arterial and venous cord blood, and placenta samples. Outcomes include: 1. Parental and close household member's patterns of self-reported use and exposure to tobacco, nicotine and cannabis using the NOTICE Tool score. Total selfuse and total exposure scores will be calculated by summing the total weekly quantity and exposure scores. Scores will then be categorised into clinically meaningful categories, with those reporting no exposure or use categorised as the reference group. 2. Tobacco, nicotine, cannabis and their metabolites concentration in ng/ml or nmol/ml. Concentrations of tobacco, nicotine, trans-3'-hydroxycotinine (3-OHcotinine), nornicotine, nicotine glucuronide and nicotine N oxide, norcotinine, NNAL, nicotelline, anabasine and anatabine [40, 41] will be summed with the total concentration in each sample recorded as total nicotine equivalents (TNE) and the nicotine metabolite ratio (NMR: 3'-hydroxycotinine/cotinine) will be calculated [42]. Similarly, delta-9-tetrahydrocannabinol-D3 (THC-D3) and delta-8 and/or delta-9 carboxy tetrahydrocannabinol-D3 (THC-COOH-D3) will be measured and summed. 3. DNA methylation patterns influenced by tobacco, nicotine and cannabis use and exposure will be identified. Methylation levels will be assessed either by immunohistological analysis of methylation intermediates (5mC, 5-hmC) or calculated and expressed as β values (β = intensity of the methylated allele (M))/

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

(Intensity of the unmethylated allele (U) + intensity of the methylated allele (M) + 100). 4. Specific tobacco, nicotine and cannabis induced genomic and DNA alterations related to the use and exposure tobacco, nicotine and cannabis products in the different participant groups (maternal, paternal, foetal placental and neonatal). Genotypes influenced by tobacco, nicotine and cannabis use and exposure will be identified. Genome-wide mRNA profiles will be sequenced and expressed as read counts per mRNA. 5. Identified genes and alternations (including gene expression) associated with tobacco, nicotine and cannabis metabolism and pregnancy clinical outcomes. Genes, including CYP2A6 and TCF7L2, with single nucleotide polymorphisms (SNPs) with minor allele frequency greater than 10% will be chosen for inclusion in analyses. PCR results will be reported as negative or positive. 6. Semen volume (mL) and quality including sperm concentrations (million per mL), count (million), progressive motility (%), vitality (%), morphology (%), pH (0-14), leucocyte counts (millions per mL). 7. CO readings will be used as continuous scores and also categorised as: 1) negligible combusted tobacco/cannabis exposure - indicated by <6 CO ppm for nonpregnant adults and <3 CO ppm for pregnant women; 2) light combusted tobacco/cannabis exposure - indicated by 7-10 CO ppm in non-pregnant adults and 4-6 CO ppm for pregnant women; 3) heavy combusted tobacco/cannabis exposure indicated by >10 CO ppm in non-pregnant adults and >6 CO ppm in pregnant women.

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

8. Saliva readings will be used as dichotomous scores, categorised as negative or positive 9. Maternal and neonatal outcomes including miscarriage, livebirth/stillbirth, gestational age (weeks), preterm birth (<37 weeks gestation), and birth weight (grams), pregnancy induced hypertension and pre-eclampsia, gestational diabetes, thyroid autoimmune disease, maternal anaemia and other factors of interest are listed in Supplementary Table 1. Sample size Approximately 80 women expecting an Indigenous baby attend antenatal care at Galangoor Duwalami Primary Healthcare Service and the Hervey Bay and Maryborough Hospitals each year, and birth at the Hervey Bay Hospital. Sample size to validate the NOTICE tool: To estimate the sensitivity and specificity of the NOTICE self-reported assessment tool for tobacco and nicotine use and exposure, assuming tobacco and nicotine exposure and use of 66% [43], a sample of 80 mothers with 5 or more assessments would allow estimation of at least 90% sensitivity and specificity for the screening tool for tobacco and nicotine use and exposure versus urinary cotinine with 95% CI within ±7% of the point estimate [44]. The collection and validation of the additional tobacco and nicotine products increases both the sensitivity and specificity of the tool. Validation will be to POC CO, saliva cotinine, and blood and urine total nicotine equivalents [40, 41]. The collection of cannabis use and

exposure measured against urinary cannabinoid concentrations provides an assessment of the tool's broader utility in pregnancy.

Using multilevel linear regression modelling with urinary cotinine levels as an outcome and adjusted for tobacco and nicotine use and exposure, to estimate a statistically significant change in tobacco and nicotine metabolism during pregnancy in an Australian Aboriginal population, with a power of 80% and alpha level of 0.05, a total of 50 mothers would be required to have a minimum of five tobacco and nicotine urine measurements during pregnancy [45] assuming an intra-class correlation of 0.3 (or lower) between urinary cotinine levels for each mother during pregnancy. With a power of 80% and alpha level of 0.05, 34 placentas would be required to be examined to estimate a 50 cm² difference in area between high and low tobacco and nicotine use/exposure.

Data analysis

Following data cleaning, checking and validation, the participants' results from the NOTICE scores for tobacco, nicotine and cannabis use and exposure, the biochemical analysis from all biochemical samples, and the maternal and neonatal outcomes will be examined to address the research objectives as described in Table 1. All data analysis will be conducted using Stata 17 (Statacorp, Texas). Missing data and outliers will be examined and reported. Results will be reported with 95% confidence intervals (95% CI) and statistical significance at alpha 0.05.

Table 1 Research outcomes and statistical analysis

Objective 1: To accurately describe parental and close household contact(s) peri-gestational patterns of use and exposure to tobacco, nicotine and cannabis products through the creation and use of a validated assessment tool.

nicotine and cannabis products through the cr	reation and use of a validated assessment tool.
Outcomes	Statistical analysis
a) Record parental and close house-hold member's patterns of self-reported use and exposure to tobacco, nicotine and cannabis using the NOTICE tool.	and percentages. The score will be used as a continuous and/or ordinal categorical variable in analyses.
b) Conduct biochemical analysis of parental and neonatal samples for tobacco, nicotine and cannabis and metabolites.	collected samples will be reported including frequency, means/medians and

c)	Compare maternal self-reported use
	and exposure with biochemical
	assessment of tobacco, nicotine and
	cannabis concentrations to establish
	the specificity, sensitivity and
	predictive validity of the NOTICE tool.

c) The sensitivity, specificity and predictive validity of the screening tool for tobacco, nicotine and cannabis use and exposure will be estimated by comparing self-reported scores with recorded cotinine saliva and CO levels at each antenatal visit.

Reliability of the NOTICE tool will also be evaluated using linear regression with urinary nicotine, tobacco and metabolite levels as the outcome and the predictive value of the self-reported scores estimated.

Objective 2: To determine the pharmacokinetic and pharmacogenomic impacts and outcomes of tobacco, nicotine and cannabis exposure.

Data and Statistical analysis Outcomes a) Investigate specific tobacco, nicotine and a, b, c) Descriptive statistics will be used to report the frequency and proportion of cannabis-induced maternal, paternal, participants with identified genetic factors related to the use of tobacco, nicotine foetal, placental and neonatal genomic and cannabis products. These factors will then be included in univariate and alternations related to the use and multivariate analyses as being present or absent to estimate their effect on exposure to tobacco, nicotine and clinical and biochemical outcomes. cannabis products. Determine tobacco, nicotine and cannabis metabolism by genotype (pharmacogenomics). c) Establish the pharmacokinetics tobacco, nicotine and cannabis in this population.

Objective 3: To describe maternal, paternal, placental, foetal and neonatal outcomes according to the use and exposure to tobacco, nicotine and cannabis products and biochemical and genomic analysis

Ou	tcomes	Data	and Statistical analysis
a)	Describe maternal, placental, foetal and neonatal outcomes		Descriptive statistics of maternal, placental, foetal and neonatal outcomes will be reported including frequency, means/medians and percentages.
b)	Determine correlations maternal, paternal, placental and neonatal outcomes and parental and foetal		Using clinical knowledge and the literature, directed acyclic graphs (DAGs) will be constructed to aid identification of causal effects/associations between 1) clinical outcomes, 2) self-reported tobacco, nicotine and cannabis use, 3) tobacco,

c) Determine correlations between maternal, paternal, placental and neonatal outcomes and genomic factors. C) Multilevel regression modelling will be used to account for the clustering effect (random effects) of each individual mother, to estimate adjusted odds ratios (logistic regression for dichotomous or categorial outcomes) or beta coefficients (linear regression for continuous data outcomes) and 95% CIs for associations. A range of adjustment factors will be considered as both fixed and random effects in the models including gestational age, infant sex, birth weight, preterm delivery, delivery method, post-partum haemorrhage, preeclampsia, maternal age, height, body mass index, parity, urinary tract infection, sexually transmitted infection, diabetes, hypertension, placental data.		tobacco, nicotine and cannabis biochemical concentrations/pharmacokinetics.		nicotine and cannabis metabolite concentrations, and 4) identified biomarkers, genetic/epigenomic/germline alterations, to determine which factors to include in statistical models.
	c)	maternal, paternal, placental and	c)	(random effects) of each individual mother, to estimate adjusted odds ratios (logistic regression for dichotomous or categorial outcomes) or beta coefficients (linear regression for continuous data outcomes) and 95% CIs for associations. A range of adjustment factors will be considered as both fixed and random effects in the models including gestational age, infant sex, birth weight, preterm delivery, delivery method, post-partum haemorrhage, preeclampsia, maternal age, height, body mass index, parity, urinary tract infection, sexually transmitted infection,

Objective 4: To describe the influences and barriers to cessation for pregnant Australian Indigenous women and their partners or close household contacts to reduce or cease tobacco and nicotine use in pregnancy

Outcor	nes	Data and Statistical analysis
a) b)	Qualitative exploration with information rich participants to understand the barriers and influences on tobacco, nicotine and cannabis cessation. Understand the population's health literacy and risk perception related to tobacco, nicotine and cannabis products peri-pregnancy.	a & b)Data will be coded and analysis will follow established processes [47] with a preliminary thematic analysis assigning meaning to the data and generating categories and subcategories. The categories most often mentioned will be identified and similarities and dissimilarities detailed. The categories will then be further grouped, and themes and subthemes identified. These will be shared with the research team for review and modification as needed. The consensus themes will be organised for analysis using NVIVO 12.

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

Ethical approval This project has been approved by the Traditional Owners of the Fraser Coast area. the Butchulla people, in conjunction with Galangoor Duwalami Primary Healthcare Service. The project has the support of the Queensland Aboriginal and Torres Strait Islander Health Council (QAIHC) and has ethics approval from Qhealth (HREC/2021/ORBW/77758) and the University of Oueensland (2021/HE002069). Discussion The overarching vision of this clinically derived, clinically driven, community based, mixed method project is to Close the Gap in Aboriginal and Torres Strait health This project takes a life-course epidemiological approach to health outcomes. outcomes, focusing on the start of life, that is, maternal and neonatal health to improve whole-of-life health outcomes. Seventy years of evidence demonstrates that maternal tobacco smoking and exposure to combusted tobacco are the leading modifiable risk behaviours associated with adverse pregnancy outcomes [48]. Currently in Australia, the assessment for tobacco and nicotine exposure during pregnancy is focused on maternal cigarette use - no information on other forms of tobacco, nicotine or cannabis use and exposure is standardly collected or considered to inform clinical care. In addition, fathers or other household members are not asked about their tobacco, nicotine and cannabis

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

use. This limited (or absent) tobacco, nicotine and cannabis screening fails to address the broad range of contemporary products that are used in Australia and thus has ramifications for the mother, the father, the children, the clinician, Indigenous populations, and the broader profile of Australian health. This project will be reported against the STOBE Guidelines and has purposeful and significant objectives. Firstly, the development of a validated tobacco and nicotine screening tool that can be translated to practice Australia-wide will enhance data reporting and the understanding of tobacco, nicotine and cannabis use and exposure to pregnancy outcomes. In addition, the use of a comprehensive and contemporary screening tool will provide an opportunity for women, families and health professionals to discuss tobacco, nicotine and cannabis use and reduction/cessation options. Secondly, addressing the absence of literature related to the metabolism of nicotine and the influence of pharmacogenomic factors in Australian Indigenous populations will be transformative. As biotechnology has evolved, there has been an increasing recognition that genetics, epigenetics, and environmental interactions impact on health outcomes. The role of genomics in understanding population risks and targeting prevention or intervention programs to reduce risk or to provide treatment based on genomic knowledge (i.e., a precision medicine approach) is of enormous public health benefit. Genomic profiling allows for the understanding of different outcomes in different populations from the same exposure. Already research exists

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

that shows that nicotine is metabolised differently in genetically different populations [49-53] and particular risks are higher or lower in populations based on these genetic differences, however, this same level of understanding has not been established for Australian Indigenous parental populations. A genome-wide mapping of specific biological samples from the local Australian Indigenous parental population in relation to their potential risk from tobacco and nicotine use and exposure and establishing [the start of] a pharmacogenomic profile will structure a precision medicine approach to health care [54, 55] for this population. Comprehension and appreciation of the barriers to tobacco, nicotine and cannabis cessation is an essential mechanism in supporting the decrease in tobacco, nicotine and cannabis use. Awareness these factors can lead to the construction of a range of education and support resources which can be selected by future pregnant women and the family to assist them to reduce or cease tobacco, nicotine and cannabis use in pregnancy. Importantly, the findings from the tobacco, nicotine and cannabis assessment and analysis will be linked to maternal and neonatal outcomes. Using the screening tool as part of standard practice in the future will provide a predictive methodology, enabling expectant mothers, families and health services to better plan birthing and post-birthing needs in situations where tobacco, nicotine and cannabis exposure is an independent factor.

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

This research project is built on respect for the value of Indigenous perspectives and their contribution to the study. Indigenous knowledge systems are incorporated into the research methodology thereby mutually enriching the research. Translation to practice is an intended outcome of this project but will not be structured until findings are available. The intention is that translation will be informed by the Indigenous participants, the Aboriginal and Torres Strait Islander health service, the researchintensive organisations supporting this research and their researchers, and the chief researcher. Limitations The study consists of some strengths and limitations. One significant strength is the recording of tobacco, nicotine and cannabis use and exposure throughout early to late pregnancy and the collection of a range of biological samples that are used to measure: Recency of maternal tobacco and nicotine exposure (maternal CO, saliva, and maternal venous blood and urine), The transfer of nicotine to the foetus (venous cord blood, amniotic fluid and neonatal urine), The return of nicotine from the foetus (arterial cord blood) The longevity of exposure (placenta and meconium) This approach minimises recall bias and provides a comprehensive and measurable assessment of tobacco and nicotine exposure over the duration of pregnancy.

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

However, the study will only recruit mothers expecting an Australian Indigenous baby in the Fraser Coast area which limits the generalizability of the findings. Additionally, being an observational study, the results will not provide the strongest evidence to establish a causal relationship between nicotine exposure or metabolism and pregnancy outcomes. **Authors contributions** AR: Conceptualization, design and methodology, establish collaborations and project administration, data collection, resources, writing original draft, review and editing. EAB: Data curation, formal analysis, investigation, methodology, software, validation, writing – review & editing. VB, IB, GM, MS: Conceptualization, supervision, writing – review & editing. GD, SO: Resources, supervision, writing - review & editing. AW: Conceptualization, methodology, resources, supervision, writing – review & editing. SB: Conceptualization, methodology, supervision, writing – review & editing. M-TW: Methodology, writing - review & editing. JM Methodology, supervision, validation, writing - review & editing. KIS: Methodology, resources, supervision, validation, writing - review & editing. **Acknowledgements** This project could not have developed without the overwhelming endorsement and governance of the Traditional Owners of the Fraser Coast area, the Butchulla people and the Butchulla Aboriginal Corporation and the Butchulla Men's Business Association. Furthermore, this project cannot progress without the consistent and

positive leadership of GD. SO and SB at Galangoor Duwalami Primary Healthcare Service and the engaged involvement of the Galangoor Duwalami teams that wrap around and support the Indigenous expectant families of the Fraser Coast area. Moreover, the cooperation and involvement of maternal services and their support teams from Wide Bay Hospital and Health Services Fraser Coast is essential in ensuring this collaborative project can achieve its aim. Fraser Coast Sullivan and Nicolaides Pathology service are sentinel in the transport of biological samples to Brisbane and the University of Oueensland and are providing this service pro bono. In terms of the design, AR conceived, designed the framework of the study, and will lead the data collection. AW, GM, VB, JB and MS guided the data collection design with Indigenous mothers and families and consulted with their respective Indigenous organisations and community members to ensure cultural and community safety and expectations were established. LB designed the statistical analysis and will undertake the data analysis. M-TW will undertake the biochemical analysis as a PhD Scholar at the University of Queensland under the supervision of JM and KS. AR is partially funded under a OHealth Advancing Clinical Research Fellowship.

Conflicts of Interest

None declared.

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

657

Abbreviations

- 658 ADHD attention-deficit/hyperactivity disorder
- 659 CO carbon monoxide

660 DAGs - directed acyclic graphs 661 mRNA - messenger ribonucleic acid 662 nAChR - nicotinic acetylcholine receptors 663 NMR - nicotine metabolite ratio 664 NRT - nicotine replacement therapy 665 POC - point of care 666 QAIHC - Queensland Aboriginal and Torres Strait Islander Health Council 667 NOTICE - Ratsch Assessment of Tobacco and Nicotine 668 SIDS - sudden infant death syndrome 669 SNPs - single nucleotide polymorphisms 670 TNE - total nicotine equivalents 671 672 673 **Supporting Information.** Supplementary Table 1: Variables of interest for analysis 674 extracted from standard National Perinatal Data Collection report, together with 675 variables of interest for this project (i.e., tobacco, nicotine and cannabis use and 676 exposure) 677

References

678

679

701

702

- 680 Simpson WI. A preliminary report on cigarette smoking and the incidence of 1. 681 prematurity. Am J Obstet Gynecol. 1957;73(4):807-15.
- 682 Avsar TS, McLeod H, Jackson L. Health outcomes of smoking during 683 pregnancy and the postpartum period: an umbrella review. BMC Pregnancy 684 Childbirth. 2021;21(1):254.
- 685 Naeve RL. Abruptio placentae and placenta previa: frequency, perinatal 3. 686 mortality, and cigarette smoking. Obstet Gynecol. 1980;55(6):701-4.
- 687 Marcoux S, Brisson J, Fabia J. The effect of cigarette smoking on the risk of 688 preeclampsia and gestational hypertension. Am J Epidemiol. 1989:130(5):950-7.
- 689 England LJ, Levine RJ, Qian C, Morris CD, Sibai BM, Catalano PM, et al.
- 690 Smoking before pregnancy and risk of gestational hypertension and preeclampsia. 691 Am J Obstet Gynecol. 2002;186(5):1035-40.
- 692 Gould GS. Havard A. Lim LL. The Psanz Smoking In Pregnancy Expert G.
- 693 Kumar R. Exposure to Tobacco, Environmental Tobacco Smoke and Nicotine in
- 694 Pregnancy: A Pragmatic Overview of Reviews of Maternal and Child Outcomes,
- 695 Effectiveness of Interventions and Barriers and Facilitators to Quitting. Int J Environ 696 Res Public Health, 2020:17(6).
- 697 7. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth 698 defects: a systematic review based on 173 687 malformed cases and 11.7 million 699 controls. Hum Reprod Update. 2011;17(5):589-604.
- 700 Yang L, Wang H, Yang L, Zhao M, Guo Y, Bovet P, et al. Maternal cigarette smoking before or during pregnancy increases the risk of birth congenital anomalies: a population-based retrospective cohort study of 12 million mother-
- 703 infant pairs. BMC Med. 2022;20(1):4.
- 704 9. Clifford A, Lang L, Chen R. Effects of maternal cigarette smoking during 705 pregnancy on cognitive parameters of children and young adults: a literature 706 review. Neurotoxicol Teratol. 2012;34(6):560-70.
- 707 Sourander A, Sucksdorff M, Chudal R, Surcel HM, Hinkka-Yli-Salomaki S, 10.
- 708 Gyllenberg D. et al. Prenatal Cotinine Levels and ADHD Among Offspring, Pediatrics. 2019;143(3). 709
- 710 Australian Institute of Health and Welfare. [Internet]. Canberra: National 11.
- 711 Perinatal Data Collection (NPDC): Australian Government; 2020 [cited 2024 3
- 712 January]. Available from: https://www.aihw.gov.au/about-our-data/our-data-
- 713 collections/national-perinatal-data-collection.
- 714 Australian Institute of Health and Welfare. [Internet]. Australia's mothers
- 715 and babies; 2023 [cited 2024 3 January]. Available from:
- https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-716
- 717 babies/contents/about.
- 718 Australian Institute of Health and Welfare, National Indigenous Australian 13.
- 719 Agency. [Internet]. Canberrra: Tier 2 Determinants of health 2.21 Health behaviours
- 720 during pregnancy: Australian Government; 2022 [cited 2024 5 January]. Available
- 721 from: https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-
- 722 during-pregnancy.


- 723 14. Australian Institute of Health and Welfare. [Internet]. Canberra: Pregnancy
- and birth outcomes for Aboriginal and Torres Strait Islander women 2016–2018.
- 725 Cat. no. IHW 234: AIHW; 2021 [cited 2023 14 October]. Available from:
- 726 https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-
- 727 <u>outcomes-indigenous-women-2016-18/contents/summary</u>.
- 728 15. Australian Institute of Health and Welfare. [Internet]. Canberra: Stillbirths
- 729 and neonatal deaths in Australia 2017 and 2018: AIHW; 2021 [cited 2024 24
- 730 January]. Available from: https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-
- 731 <u>96ac-e6cc221d79b8/aihw-per-115.pdf.aspx.</u>
- 732 16. Benowitz NL, Hukkanen J, Jacob P, III. Nicotine Chemistry, Metabolism,
- 733 Kinetics and Biomarkers. In: Henningfield JE, London ED, Pogun S, editors. Nicotine
- 734 Psychopharmacology. Handbook of Experimental Pharmacology. 192: Springer
- 735 Berlin Heidelberg; 2009. p. 29-60.
- 736 17. McGrath-Morrow SA, Gorzkowski J, Groner JA, Rule AM, Wilson K, Tanski SE,
- et al. The Effects of Nicotine on Development. Pediatrics. 2020;145(3).
- Hukkanen J, Jacob P, 3rd, Benowitz NL. Metabolism and disposition kinetics
- 739 of nicotine. Pharmacol Rev. 2005;57(1):79-115.
- 740 19. Tizabi Y, Getachew B, Copeland RL, Aschner M. Nicotine and the nicotinic
- 741 cholinergic system in COVID-19. FEBS J. 2020;287(17):3656-63.
- 742 20. Banerjee S, Deacon A, Suter MA, Aagaard KM. Understanding the Placental
- 743 Biology of Tobacco Smoke, Nicotine, and Marijuana (THC) Exposures During
- 744 Pregnancy. Clin Obstet Gynecol. 2022;65(2):347-59.
- 745 21. Pintican D, Poienar AA, Strilciuc S, Mihu D. Effects of maternal smoking on
- 746 human placental vascularization: A systematic review. Taiwan J Obstet Gynecol.
- 747 2019;58(4):454-9.
- 748 22. Beltrán-Castillo S, Bravo K, Eugenín J. Impact of Prenatal Nicotine Exposure
- on Placental Function and Respiratory Neural Network Development. In: Gonzalez-
- 750 Ortiz M, editor. Advances in Maternal-Fetal Biomedicine: Cellular and Molecular
- 751 Mechanisms of Pregnancy Pathologies. Cham: Springer International Publishing;
- 752 2023. p. 233-44.
- 753 23. Alzu'bi A. Middleham W. Shoaib M. Clowry GI. Selective Expression of
- 754 Nicotinic Receptor Sub-unit mRNA in Early Human Fetal Forebrain. Front Mol
- 755 Neurosci. 2020;13:72.
- 756 24. National Research Council (US) and Institute of Medicine (US) Committee on
- 757 Integrating the Science of Early Childhood Development, [Internet], Washington
- 758 (DC): From Neurons to Neighborhoods: The Science of Early Childhood
- 759 Development. The Developing Brain: National Academies Press 2000 [cited 2024 29]
- 760 January]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK225562/.
- 761 25. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies,
- dare we recommend nicotine replacement therapy in pregnant women and
- adolescents? Neurotoxicol Teratol. 2008;30(1):1-19.
- 764 26. Buck IM, O'Neill HC, Stitzel IA. Developmental nicotine exposure elicits
- 765 multigenerational disequilibria in proBDNF proteolysis and glucocorticoid signaling
- in the frontal cortices, striata, and hippocampi of adolescent mice. Biochem
- 767 Pharmacol. 2019;168:438-51.

- 768 27. Bednarczuk N, Milner A, Greenough A. The Role of Maternal Smoking in
- 769 Sudden Fetal and Infant Death Pathogenesis. Front Neurol. 2020;11:586068.
- 770 28. Benowitz NL. Clinical pharmacology of nicotine. Annu Rev Med. 1986;37:21-
- 771 32.
- 772 29. Benowitz NL, Kuyt F, Jacob P, 3rd, Jones RT, Osman AL. Cotinine disposition
- 773 and effects. Clin Pharmacol Ther. 1983;34(5):604-11.
- 30. Benowitz NL, Dains KM, Dempsey D, Yu L, Jacob P, 3rd. Estimation of nicotine
- dose after low-level exposure using plasma and urine nicotine metabolites. Cancer
- 776 Epidemiol Biomarkers Prev. 2010;19(5):1160-6.
- 777 31. Dempsey D, Jacob P, 3rd, Benowitz NL. Accelerated metabolism of nicotine
- and cotinine in pregnant smokers. J Pharmacol Exp Ther. 2002;301(2):594-8.
- 779 32. Arger CA, Taghavi T, Heil SH, Skelly J, Tyndale RF, Higgins ST. Pregnancy-
- 780 Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During
- Antepartum and Postpartum. Nicotine Tob Res. 2019;21(12):1706-10.
- 782 33. Dempsey D, Jacob P, 3rd, Benowitz NL. Nicotine metabolism and elimination
- 783 kinetics in newborns. Clin Pharmacol Ther. 2000;67(5):458-65.
- 784 34. Feyerabend C, Russell MAH. Effect of urinary pH and nicotine excretion rate
- on plasma nicotine during cigarette smoking and chewing nicotine gum. Br J Clin
- 786 Pharmacol. 1978;5(4):293-7.
- 787 35. Taghavi T, Arger CA, Heil SH, Higgins ST, Tyndale RF. Longitudinal Influence
- 788 of Pregnancy on Nicotine Metabolic Pathways. Journal of Pharmacology and
- 789 Experimental Therapeutics. 2018;364(2):238-45.
- 790 36. The National Health and Medical Research Council, the Australian Research
- 791 Council, and Universities Australia. National Statement on Ethical Conduct in Human
- Research 2007 (Updated 2018). Canberra: Commonwealth of Australia; 2018.
- 793 37. Geia LK, Hayes B, Usher K. Yarning/Aboriginal storytelling: towards an
- understanding of an Indigenous perspective and its implications for research
- 795 practice. Contemp Nurse. 2013;46(1):13-7.
- 796 38. Bessarab D, Ng'andu B. Yarning About Yarning as a Legitimate Method in
- 797 Indigenous Research. International Journal of Critical Indigenous Studies.
- 798 2010:3(1):37-50.
- 799 39. Walker M, Fredericks B, Mills K, Anderson D. "Yarning" as a method for
- 800 community-based health research with Indigenous women: the Indigenous
- Women's Wellness Research Program. Health Care Women Int. 2014;35(10):1216-
- 802 26.
- 803 40. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al.
- 804 Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. Nicotine Tob
- 805 Res. 2020;22(7):1086-97.
- 806 41. Benowitz NL, St Helen G, Nardone N, Cox LS, Jacob P. Urine Metabolites for
- 807 Estimating Daily Intake of Nicotine From Cigarette Smoking. Nicotine Tob Res.
- 808 2020;22(2):288-92.
- 809 42. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P, III. Nicotine metabolite
- ratio as a predictor of cigarette consumption. Nicotine Tobacco Res. 2003;5(5):621-
- 811 4

- 43. Gilligan C, Sanson-Fisher R, Eades S, Wenitong M, Panaretto K, D'Este C.
- Assessing the accuracy of self-reported smoking status and impact of passive smoke
- 814 exposure among pregnant Aboriginal and Torres Strait Islander women using
- cotinine biochemical validation. Drug Alcohol Rev. 2010;29(1):35-40.
- 816 44. Malhotra RK, Indrayan A. A simple nomogram for sample size for estimating
- sensitivity and specificity of medical tests. Indian J Ophthalmol. 2010;58(6):519-22.
- 818 45. McNeish DM. Modeling sparsely clustered data: design-based, model-based,
- and single-level methods. Psychol Methods. 2014;19(4):552-63.
- 820 46. Vaz LR, Coleman T, Cooper S, Aveyard P, Leonardi-Bee J, team St. The
- Nicotine Metabolite Ratio in Pregnancy Measured by trans-3'-Hydroxycotinine to
- 822 Cotinine Ratio: Characteristics and Relationship With Smoking Cessation. Nicotine
- 823 Tob Res. 2015;17(11):1318-23.
- 824 47. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative
- 825 Research in Psychology. 2006;3(2):77-101.
- 826 48. National Center for Chronic Disease Prevention and Health Promotion (US)
- Office on Smoking and Health. Reproductive Outcomes. The Health Consequences of
- 828 Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta (GA):
- 829 Centers for Disease Control and Prevention (US); 2014. p. 461-521.
- 830 49. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P, 3rd. Slower metabolism and
- reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl
- 832 Cancer Inst. 2002;94(2):108-15.
- 833 50. Cecil CA, Walton E, Smith RG, Viding E, McCrory EJ, Relton CL, et al. DNA
- methylation and substance-use risk: a prospective, genome-wide study spanning
- gestation to adolescence. Transl Psychiatry. 2016;6(12):e976.
- 836 51. Chen X, Woodcroft KJ. Polymorphisms in metabolic genes CYP1A1 and
- 637 GSTM1 and changes in maternal smoking during pregnancy. Nicotine Tob Res.
- 838 2009;11(3):225-33.
- 839 52. Keskitalo K, Broms U, Heliovaara M, Ripatti S, Surakka I, Perola M, et al.
- Association of serum cotinine level with a cluster of three nicotinic acetylcholine
- receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet.
- 842 2009:18(20):4007-12.
- 843 53. Marceau K, Palmer RH, Neiderhiser JM, Smith TF, McGeary JE, Knopik VS.
- Passive rGE or developmental gene-environment cascade? An investigation of the
- role of xenobiotic metabolism genes in the association between smoke exposure
- during pregnancy and child birth weight. Behav Genet. 2016;46(3):365-77.
- 847 54. Allenby CE, Boylan KA, Lerman C, Falcone M. Precision Medicine for Tobacco
- 848 Dependence: Development and Validation of the Nicotine Metabolite Ratio. I
- 849 Neuroimmune Pharmacol. 2016;11(3):471-83.
- 850 55. Cheng YY, Nunn J, Skinner J, Rambaldini B, Boughtwood T, Calma T, et al. A
- Pathway to Precision Medicine for Aboriginal Australians: A Study Protocol.
- 852 Methods Protoc. 2021;4(2):42.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.





Participant polo



Participant Onesie



NicOTIne, tobacco and Cannabis use and Exposure (NOTICE) assessment tool

To calculate self-use (SU) score:

Self-Use score calculated for each weekly product.

Quantity reported	Use	Score
0	None	0
1 - 70	Low	1
71 - 140	Medium	2
141 +	High	3

Total self-use score = sum of all weekly self-use scores.

To calculate total exposure (E) score:

Exposure score calculated for each weekly product exposed to.

Quantity	Exposure	Quantity Score
0	None	0
1 - 70	Low	1
71 - 140	Medium	2
141 +	High	3

Exposure	Exposure
0	No known exposure
1	Some limited exposure, e.g. outdoor
2	Moderate exposure, e.g. indoor but restricted to certain areas
3	No restriction, e.g. full exposure in the house, in bedroom or car.

Exposure score = weekly quantity score x weekly exposure score (range 0 - 9)

Total exposure score = sum of all exposure scores.

Author Angela Ratsch: NicOTIne tobacco and Cannabis use and Exposure (NOTICE) assessment tool Version 1, 2022

NOTICE Assessment Tool